Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16890324 | 0.92 | EPHX1 (0.52) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL17975431 | 0.88 | ALDH1A1 (0.55) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL17975428 | 0.87 | EPHX1 (0.52) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL10071176 | 0.85 | EPHX1 (0.60) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL11800970 | 0.85 | EPHX1 (0.50) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL6338852 | 0.83 | — | — | |
| SCHEMBL2625566 | 0.83 | EPHX1 (0.48) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL11568538 | 0.82 | EPHX1 (0.44) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL17616092 | 0.82 | EPHX1 (0.49) | EPHX1HPGDL3MBTL1KDM4EKMT2A | |
| SCHEMBL11128751 | 0.82 | EPHX1 (0.47) | EPHX1HPGDL3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110046982-A1 | METHODS AND COMPOSITIONS RELATED TO VIRAL INHIBITION | CLEMSON UNIVERSITY RESEARCH FOUNDATION (CURF) (US) | 2011-02-24 | — | — | US | disclosed |
| EP-1279667-B1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | MITSUI CHEMICALS INC (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-6861534-B2 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2005-03-01 | — | — | US | disclosed |
| EP-1279667-A1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2003-01-29 | — | — | EP | disclosed |
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | PIGS, DEK, B2M | EPHX1 4090/4885HPGD 2626/4885L3MBTL1 2705/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 34/4885L3MBTL1 2601/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX1 635/4885HPGD 37/4885L3MBTL1 2632/4885 |
| US-20110046982-A1 | METHODS AND COMPOSITIONS RELATED TO VIRAL INHIBITION | EIF2AK2, NSUN2, NSUN3 | EPHX1 4154/4885HPGD 4686/4885L3MBTL1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.